Eyenovia said on Friday it will discontinue a late-stage study for its experimental drug-device combination to treat near-sightedness and cut about 50% of its workforce.
(Reuters) -Eyenovia will discontinue a late-stage study for its experimental drug-device combination to treat near-sightedness in children after it failed to slow the condition's progression, sending ...
Presbyopia is an age-related refractive condition marked by a gradual decline in near vision, typically emerging between ages ...
It happens when a parasite that can be found in water invades the eye, damaging the cornea, causing severe pain and ...
Aldeyra received an FDA CRL for reproxalap, necessitating an additional study for DED approval. Read why I continue to rate ...
In June 2024, a canalicular gel device (Lacrifill, Nordic Pharma) was introduced to the US market, and a recent study has ...
AbbVie stock drops after emraclidine fails Phase 2 trials for schizophrenia, raising questions about its neuroscience ...
AbbVie (ABBV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Geoff Meacham ...
Terence Flynn, an analyst from Morgan Stanley, reiterated the Buy rating on AbbVie (ABBV – Research Report). The associated price target ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback